Cardinal Health, Inc.

Hello, and welcome to second quarter fiscal year 2025 Cardinal Health Incorporated earnings conference call. My name is George, and I'll be a coordinator for today's event. Please note this conference is being recorded, and for the duration of the call, your lines will be in listen-only mode. However, you will have the opportunity to ask questions towards the end of the presentation, and this can be done by pressing star 1 on your telephone keypad. And also, we'd like to ask everybody to please limit themselves to one question each, telling the maximum of the attendees to ask a question. If you require assistance at any point, please press star zero and you'll be connected to an operator. I'd like to have a call over to your host today, Mr. Matt Sims, Vice President of Investor Relations, to begin today's conference. Please go ahead.

Hello, and welcome to this morning's Cardinal Health Second Quarter Fiscal 25 Earnings Conference Call, and thank you for joining us. With me today are Cardinal Health CEO, Jason Holler, and our CFO, Aaron Ault. You can find this morning's earnings press release and investor presentation on the investor relations section of our website at ir.cardinalhealth.com. Since we will be making forward-looking statements today, let me remind you that the matters addressed in these statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statement slide at the beginning of our investor presentation for a description of these risks and uncertainties. Please note that during our discussion today, the comments will be on a non-GAAP basis, unless specifically called out as GAAP. GAAP to non-GAAP reconciliation for all relevant periods can be found in the supporting schedules attached to our press release. For the Q&A portion of today's call, we kindly ask that you limit questions to one per participant so that we can try and give everyone an opportunity. With that, I will now turn the call over to Jason. Thank you, and good morning, everyone.

Today, we reported strong second quarter results, accelerating the momentum that we've built over the last couple of years. Overall, the performance was led by robust demand across our largest and most significant business, pharmaceutical and specialty solutions, and our relentless focus on the execution of our simplification strategy to best serve our customers. Notably, we're seeing strength in brand, specialty, generics, and consumer health, as we're well positioned within a growing market. As a result of the significant strategic and operational actions we've taken, we remain bullish about our position in the healthcare industry and confident in our strategic direction for the future. And with this confidence, we are pleased to again raise our fiscal 25 enterprise guidance, which Aaron will cover in more detail shortly. We see opportunities to continue building upon the resiliency of the pharma business and drive consistent growth particularly within specialty. Today's closing of the acquisition of a majority stake in GI Alliance, which in conjunction with our recently completed integrated oncology network transaction, will allow us to continue to expand across key therapeutic areas and generate additional value for our customers, patients, and shareholders. Later on, I'll talk more about how these investments accelerate our strategy, but for now I'd like to officially welcome both the ION and GI Alliance teams to Cardinal Health, and thank them for their focus and dedication as we work together to unlock new opportunities. In GMPD, while Q2 was below our expectations, the team remains focused on executing the GMPD improvement plan with positive progress on our cost optimization initiatives during the quarter. And across our other businesses, nuclear, at-home, and opti-freight, we see robust demand across these three faster-growing and higher-margin businesses. A long-term potential for growth is evident, and we intend to continue to invest across these businesses to add scale and capabilities. In summary, we are pleased with this quarter's results, which reflect our efforts to accelerate our strategy, execute with precision, and drive sustainable long-term growth. With that, I'll turn it over to Aaron to review our results and updated guidance.